All the
latest

August 04, 2026

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Second quarter total revenue of $214 million,  Crysvita ® revenue of $156 million and Dojolvi ® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path

Read more
July 28, 2026

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

NOVATO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at

Read more